BEFORE THE BELL-Incyte rises after selling therapies to Lilly
NEW YORK |
NEW YORK Dec 21 (Reuters) - Shares of Incyte Corp (INCY.O) rose 5.5 percent to $8.96 in premarket trading on Monday after the company sold global rights to its oral anti-inflammatory and autoimmune therapies to Eli Lilly and Co (LLY.N) for up to $755 million.
For details, see [ID:nSGE5BK0F3]
(Reporting by Ryan Vlastelica)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters